Zhengrui Xiao
Overview
Explore the profile of Zhengrui Xiao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
68
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xiao Z, He Z, Nguyen H, Thakur R, Hammami M, Narvel H, et al.
Ann Hematol
. 2024 Jun;
103(9):3453-3461.
PMID: 38864906
The pathophysiology of immune thrombocytopenia (ITP) involves immune-mediated platelet destruction. The presence of adipose tissue in obese individuals creates an inflammatory environment that could potentially impact the clinical course and...
2.
Zhang J, Zhang Y, Xiao Z, Tan J, Zhang H, Yu J
Membranes (Basel)
. 2024 Apr;
14(4).
PMID: 38668100
Investigating the oxygen transport law within the Membrane Electrode Assembly at intermediate temperatures (80-120 °C) is crucial for enhancing fuel cell efficiency. This study analyzed the resistance to oxygen transport...
3.
Xiao Z, Murakhovskaya I
Front Immunol
. 2023 Aug;
14:1215216.
PMID: 37575230
The pathophysiology of immune thrombocytopenia (ITP) is complex and encompasses innate and adaptive immune responses, as well as megakaryocyte dysfunction. Rituximab is administered in relapsed cases and has the added...
4.
Kalac M, Jain S, Tam C, Xiao Z, Montanari F, Kanakry J, et al.
Blood Adv
. 2023 Feb;
7(14):3760-3763.
PMID: 36790924
No abstract available.
5.
Xiao Z, Murakhovskaya I
Pharmaceutics
. 2022 May;
14(5).
PMID: 35631621
Autoimmune hemolytic anemia (AIHA) is a rare disorder characterized by the autoantibody-mediated destruction of red blood cells, and treatments for it still remain challenging. Traditional first-line immunosuppressive therapy, which includes...
6.
Kaur G, Saldarriaga M, Shah N, Catamero D, Yue L, Ashai N, et al.
Clin Lymphoma Myeloma Leuk
. 2020 Dec;
21(4):e384-e397.
PMID: 33339770
Background: Multiple myeloma (MM) in Hispanics has never been studied. We therefore sought to determine the clinical characteristics and overall survival in MM of Hispanics compared to non-Hispanic whites (NHW)...
7.
Xiao Z, Acuna-Villaorduna A, Mantzaris I
Leuk Lymphoma
. 2019 Aug;
61(1):243-245.
PMID: 31429613
No abstract available.
8.
Deng L, Hardardottir H, Song H, Xiao Z, Jiang C, Wang Q, et al.
Cancer Med
. 2019 Apr;
8(6):3269-3277.
PMID: 30993899
Lung cancer as a second primary malignancy (lung-2) is increasingly common, but its prognosis is poorly understood. This study aims to examine the overall and cancer-specific survival of patients diagnosed...
9.
Xiao Z, Yin G, Ni Y, Qu X, Wu H, Lu H, et al.
Biomed Pharmacother
. 2017 Sep;
95:743-748.
PMID: 28888211
Objective: To illustrate the association of MDR1 (Multidrug Resistance 1) polymorphisms at loci 1236, 2677, 3435 and the prognosis of multiple myeloma (MM) in Jiangsu population. Methods: A total of...
10.
Xiao Z, Li J, Miao K
Curr Stem Cell Res Ther
. 2016 Jul;
12(1):14-18.
PMID: 27396370
Since the improvement of chemotherapy and innovation of rituximab, about 60% of patients with diffuse large B cell lymphoma (DLBCL) could receive long-term survival after firstline therapy. Around 30% fail...